Moderna's stock is on track for its highest close since September 2024, indicating a shift in investor sentiment from technology stocks to more defensive biopharma investments. This shift reflects broader market trends where investors are seeking stability in the biotech sector.
Author
Mackenzie Tatananni
Source
Barron's
Published
Friday, June 26, 2026
Time
2:03 PM EDT
Skip to Main Content
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
Why Moderna Stock Is Soaring and Leading the S&P 500 Today
Moderna stock was on pace for its highest close since September 2024. (Adam Glanzman/Bloomberg)
Modernastock was pacing toward its highest close in nearly two years on Friday. But the rally signaled more than an investor rotation away from tech and into defensive biopharma.
